Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul;13(7):e230158.
doi: 10.57264/cer-2023-0158. Epub 2024 Jun 13.

Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature review

Jose Nativi-Nicolau  1 , Ali Yilmaz  2 , Noel Dasgupta  3 , Richard Macey  4 , James Cochrane  4 , Judith Peatman  4 , Catherine Summers  5 , Jennifer Luth  5 , Ronald Zolty  6
Affiliations

Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature review

Jose Nativi-Nicolau et al. J Comp Eff Res. 2024 Jul.

Abstract

Aim: The six-minute walk test (6MWT) is a common measure of functional capacity in patients with heart failure (HF). Primary clinical study end points in cardiomyopathy (CM) trials, including transthyretin-mediated amyloidosis with CM (ATTR-CM), are often limited to hospitalization and mortality. Objective: To investigate the relationship between the 6MWT and hospitalization or mortality in CM, including ATTR-CM. Method: A PRISMA-guided systematic literature review was conducted using search terms for CM, 6MWT, hospitalization and mortality. Results: Forty-one studies were identified that reported 6MWT data and hospitalization or mortality data for patients with CM. The data suggest that a greater 6MWT distance is associated with a reduced risk of hospitalization or mortality in CM. Conclusion: The 6MWT is an accepted alternative end point in CM trials, including ATTR-CM.

Keywords: 6MWT; ATTR; cardiomyopathy; hospitalization; mortality; six-minute walk test; transthyretin-mediated amyloidosis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. PRISMA diagram.
See this image and copyright information in PMC

References

    1. Bittner V, Weiner DH, Yusuf S et al. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. JAMA 270(14), 1702–1707 (1993). - PubMed
    1. Casanova C, Celli BR, Barria P et al. The 6-min walk distance in healthy subjects: reference standards from seven countries. Eur. Respir. J. 37(1), 150–156 (2011). - PubMed
    1. McCabe N, Butler J, Dunbar SB, Higgins M, Reilly C. Six-minute walk distance predicts 30-day readmission after acute heart failure hospitalization. Heart Lung 46(4), 287–292 (2017). - PubMed
    1. Spertus JA, Jones PG, Sandhu AT, Arnold SV. Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review. J. Am. Coll. Cardiol. 76(20), 2379–2390 (2020). - PubMed
    1. Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am. J. Respir. Crit. Care Med. 158(5), 1384–1387 (1998). - PubMed

Publication types

MeSH terms

Supplementary concepts